Merck & Company Inc (MRK)vsPersonalis Inc (PSNL)
MRK
Merck & Company Inc
$146.99
-0.16%
HEALTHCARE · Cap: $368.89B
PSNL
Personalis Inc
$15.86
-0.63%
HEALTHCARE · Cap: $1.71B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 83320% more annual revenue ($67.38B vs $80.77M). MRK leads profitability with a 3.6% profit margin vs -147.7%. MRK earns a higher WallStSmart Score of 44/100 (D).
MRK
Hold44
out of 100
Grade: D
PSNL
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-72.9%
Fair Value
$84.87
Current Price
$146.99
$62.12 premium
Margin of Safety
-42.9%
Fair Value
$6.23
Current Price
$15.86
$9.63 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 41.2%
Generating 5.5B in free cash flow
Revenue surging 76.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.7x book value
4.7% revenue growth
ROE of 5.5% — below average capital efficiency
3.6% margin — thin
Trading at 8.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PSNL
The strongest argument for PSNL centers on Revenue Growth, Debt/Equity. Revenue growth of 76.6% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Revenue Growth, Return on Equity. A P/E of 151.0x leaves little room for execution misses. Thin 3.6% margins leave little buffer for downturns.
Bear Case : PSNL
The primary concerns for PSNL are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
MRK profiles as a value stock while PSNL is a hypergrowth play — different risk/reward profiles.
PSNL carries more volatility with a beta of 2.36 — expect wider price swings.
PSNL is growing revenue faster at 76.6% — sustainability is the question.
MRK generates stronger free cash flow (5.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (44/100 vs 27/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Personalis Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Personalis, Inc. is a global cancer genomics company. The company is headquartered in Menlo Park, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?